BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 26397892)

  • 1. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
    Mazarei G; Leavitt BR
    J Huntingtons Dis; 2015; 4(2):109-18. PubMed ID: 26397892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
    Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
    Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
    Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
    J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.
    Boros FA; Klivényi P; Toldi J; Vécsei L
    Expert Opin Ther Targets; 2019 Jan; 23(1):39-51. PubMed ID: 30449219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
    Song P; Ramprasath T; Wang H; Zou MH
    Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
    Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
    Front Immunol; 2022; 13():997240. PubMed ID: 36263032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
    Fujigaki H; Yamamoto Y; Saito K
    Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
    Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
    J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered kynurenine pathway metabolism and association with disease activity in patients with systemic lupus.
    Eryavuz Onmaz D; Tezcan D; Yilmaz S; Onmaz M; Unlu A
    Amino Acids; 2023 Dec; 55(12):1937-1947. PubMed ID: 37925676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indoleamine 2,3-dioxygenase (IDO1) - Can dendritic cells and monocytes expressing this moonlight enzyme change the phase of Parkinson's Disease?
    Gonçalves M; Rodrigues-Santos P; Januário C; Cosentino M; Pereira FC
    Int Immunopharmacol; 2024 May; 133():112062. PubMed ID: 38652967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of IDO1 enzyme activity in normal and malignant tissues.
    Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
    Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
    Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise and the Kynurenine pathway: Current state of knowledge and results from a randomized cross-over study comparing acute effects of endurance and resistance training.
    Joisten N; Kummerhoff F; Koliamitra C; Schenk A; Walzik D; Hardt L; Knoop A; Thevis M; Kiesl D; Metcalfe AJ; Bloch W; Zimmer P
    Exerc Immunol Rev; 2020; 26():24-42. PubMed ID: 32139353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.
    Shen H; Xu X; Bai Y; Wang X; Wu Y; Zhong J; Wu Q; Luo Y; Shang T; Shen R; Xi M; Sun H
    Eur J Med Chem; 2023 May; 251():115258. PubMed ID: 36917881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation.
    Mondanelli G; Coletti A; Greco FA; Pallotta MT; Orabona C; Iacono A; Belladonna ML; Albini E; Panfili E; Fallarino F; Gargaro M; Manni G; Matino D; Carvalho A; Cunha C; Maciel P; Di Filippo M; Gaetani L; Bianchi R; Vacca C; Iamandii IM; Proietti E; Boscia F; Annunziato L; Peppelenbosch M; Puccetti P; Calabresi P; Macchiarulo A; Santambrogio L; Volpi C; Grohmann U
    Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3848-3857. PubMed ID: 32024760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour: Both effects are reversed by inhibition of indoleamine 2,3-dioxygenase.
    Fuertig R; Azzinnari D; Bergamini G; Cathomas F; Sigrist H; Seifritz E; Vavassori S; Luippold A; Hengerer B; Ceci A; Pryce CR
    Brain Behav Immun; 2016 May; 54():59-72. PubMed ID: 26724575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
    Front Immunol; 2022; 13():807271. PubMed ID: 35173722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
    Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
    Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
    Zarzecki MS; Cattelan Souza L; Giacomeli R; Silva MRP; Prigol M; Boeira SP; Jesse CR
    Neurochem Res; 2020 Dec; 45(12):2959-2977. PubMed ID: 33040279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.